Abstract:Abstract Background LRIG1, the founding member of the LRIG (leucine-rich repeat and immunoglobulin-like domain) family of transmembrane proteins, is a negative regulator of receptor tyrosine kinases and a tumour suppressor. Decreased LRIG1 expression is consistently observed in cancer, across diverse tumour types, and is linked to poor patient prognosis. However, mechanisms by which LRIG1 is repressed are not fully understood. Silencing of LRIG1 through promoter CpG island methylation has been reported in colorectal and cervical cancer but studies in breast cancer remain limited. Methods In silico analysis of human breast cancer patient data were used to demonstrate a correlation between DNA methylation and LRIG1 silencing in basal/triple-negative breast cancer, and its impact on patient survival. LRIG1 gene expression, protein abundance, and methylation enrichment were examined by quantitative reverse-transcription PCR, immunoblotting, and methylation immunoprecipitation, respectively, in breast cancer cell lines in vitro. We examined the impact of global demethylation on LRIG1 expression and methylation enrichment using 5-aza-2’-deoxycytidine. We also examined the effects of targeted demethylation of the LRIG1 CpG island, and transcriptional activation of LRIG1 expression, using the RNA guided deadCas9 transactivation system. Results Across breast cancer subtypes, LRIG1 expression is lowest in the basal/triple-negative subtype so we investigated whether differential methylation may contribute to this. Indeed, we find that LRIG1 CpG island methylation is most prominent in basal/triple-negative cell lines and patient samples. Use of the global demethylating agent 5-aza-2’-deoxycytidine decreases methylation leading to increased LRIG1 transcript expression in basal/triple-negative cell lines, while having no effect on LRIG1 expression in luminal/ER-positive cell lines. Using a CRISPR/deadCas9 (dCas9)-based targeting approach, we demonstrate that TET1-mediated demethylation (Tet1-dCas9) along with VP64-mediated transcriptional activation (VP64-dCas9) at the CpG island, increased endogenous LRIG1 expression in basal/triple-negative breast cancer cells, without transcriptional upregulation at predicted off-target sites. Activation of LRIG1 by the dCas9 transactivation system significantly increased LRIG1 protein abundance, reduced site-specific methylation, and reduced cancer cell viability. Our findings suggest that CRISPR-mediated targeted activation may be a feasible way to restore LRIG1 expression in cancer. Conclusions Our study contributes novel insight into mechanisms which repress LRIG1 in triple-negative breast cancer and demonstrates for the first time that targeted de-repression of LRIG1 in cancer cells is possible. Understanding the epigenetic mechanisms associated with repression of tumour suppressor genes holds potential for the advancement of therapeutic approaches.

Methyltransferase 3A-Mediated Promoter Methylation Represses Retinoic Acid Receptor Responder 3 Expression in Basal-Like Breast Cancer

Abstract 1397: the Regulation of DNMT3B Expression by Lncrna-Ncrms in Cancer

Epigenetic Silencing Oflrrc3bin Colorectal Cancer

Critical Role of Delta Dnmt3b4/2 in Regulating Rassf1a Promoter-Specific Dna Methylation in Non-Small Cell Lung Cancer

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy

RUNX3 Gene Promoter Demethylation by 5-Aza-cdr Induces Apoptosis in Breast Cancer MCF-7 Cell Line

Decreased Expression of EZH2 Reactivates RASSF2A by Reversal of Promoter Methylation in Breast Cancer Cells

DNMT3A facilitates colorectal cancer progression via regulating DAB2IP mediated MEK/ERK activation

Promoter Methylation Of The Retinoic Acid Receptor Beta2 (Rar Beta 2) Is Associated With Increased Risk Of Breast Cancer: A Prisma Compliant Meta-Analysis

RARRES1 identified by comprehensive bioinformatic analysis and experimental validation as a promising biomarker in Skin Cutaneous Melanoma

Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer

Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.

Retinoid X Receptor-α Expression Suppression and its Promoter Methylation Associates with β-catenin Expression in Colorectal Cancer

Retinoic Acid-Induced 2 (RAI2) is a Novel Tumor Suppressor, and Promoter Region Methylation of RAI2 is a Poor Prognostic Marker in Colorectal Cancer.

RNA Interference-Mediated Knockdown of DNA Methyltransferase 1 Leads to Promoter Demethylation and Gene Re-Expression in Human Lung and Breast Cancer Cells

Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer

Deoxyribonucleic Acid Methyltransferase 3b Promotes Epigenetic Silencing Through Histone 3 Chromatin Modifications In Pituitary Cells

An essential role for DNA methyltransferase 3a in melanoma tumorigenesis

Estrogen Receptor Β Promoter Methylation: a Potential Indicator of Malignant Changes in Breast Cancer.

Hypermethylated RASAL1's promotive role in chemoresistance and tumorigenesis of choriocarcinoma was regulated by TET2 but not DNMTs

Methylation of RASSF10 Promotes Cell Proliferation and Serves As a Docetaxel Resistant Marker in Human Breast Cancer.